Andrei V. Bakin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrei V. Bakin has a total of 264 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Gupta
Division of Pediatric Oncology Roswell Park Comprehensive Cancer Center Buffalo New York USA
11 shared publications - Joyce Ellen Ohm
Department of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
11 shared publications James Ofengand
University of Miami, Department of Biochemistry and Molecular Biology, School of Medicine, Miami, Florida 33101
9 shared publications- Christos Fountzilas
Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USA
8 shared publications Jeffrey C. Martin
7 shared publicationsJennie R. Sims
7 shared publications
Latest Publications
- 10 November 2026
- Published by Elsevier in Cancer Letters
Effective Targeting of p53-Mutant Colorectal and Pancreatic Cancers by Combinatorial Therapeutic Strategy
- 10 November 2026
- Published by Elsevier in Cancer Letters
Effective Targeting of p53-Mutant Colorectal and Pancreatic Cancers by Combinatorial Therapeutic Strategy
- 7 March 2026
- Published by Wiley in International Journal of Cancer
- Vol. 158 (12) , 3300-3311
TP53 mutation is associated with improved disease control in patients with advanced RAS wild‐type colorectal adenocarcinoma treated with cetuximab and pembrolizumab
Immunotherapy with checkpoint inhibitors targeting the PD1/PD‐L1 and CTLA4 pathways has limited activity in patients with microsatellite stable (MSS) colorectal adenocarcinoma (CRC). In a prior study, the combination of cetuximab and pembrolizumab failed to improve outcomes for patients with advanced RAS wild‐type (RAS wt ) CRC. In this post hoc secondary analysis, we show that the cetuximab and pembrolizumab‐treated patients with TP53 mutant (p53 mt ) tumors had significantly higher progression‐free survival (PFS) and a decrease in tumor burden compared to patients with TP53 wild‐type (p53 wt ) tumors but no difference in overall survival compared to patients with p53 wt tumors. The gene set enrichment analysis showed a uniform upregulation of multiple metabolic and immune gene sets, including NK‐mediated immunity and IL‐12 pathway, while the IL6 pathway was downregulated. There were no overlapping transcriptional alterations between the p53 mt and p53 wt groups with treatment that remain constant despite the therapeutic intervention. Functional overlap with treatment in both groups in the proliferative, immune, and metabolic pathways were identified. In the baseline tumor samples, the number of PD‐L1 + tumor cells was significantly higher in p53 mt tumors while the number of OX40 − /AE1_AE3 − /PD‐L1 − non‐tumor cells, positive for either LAG3, CTLA4 or TIM3, was significantly higher in p53 wt tumors. In conclusion, TP53 status was prognostic of improved PFS with cetuximab plus pembrolizumab in RAS wt CRC. Future studies evaluating immune‐oncology agents in patients with MSS, RAS wt CRC should include TP53 as an integrated biomarker and evaluate its performance as a positive predictive biomarker (ClinicalTrials.gov NCT02713373).
- 7 March 2026
- Published by Wiley in International Journal of Cancer
- Vol. 158 (12) , 3300-3311
TP53 mutation is associated with improved disease control in patients with advanced RAS wild‐type colorectal adenocarcinoma treated with cetuximab and pembrolizumab
Immunotherapy with checkpoint inhibitors targeting the PD1/PD‐L1 and CTLA4 pathways has limited activity in patients with microsatellite stable (MSS) colorectal adenocarcinoma (CRC). In a prior study, the combination of cetuximab and pembrolizumab failed to improve outcomes for patients with advanced RAS wild‐type (RAS wt ) CRC. In this post hoc secondary analysis, we show that the cetuximab and pembrolizumab‐treated patients with TP53 mutant (p53 mt ) tumors had significantly higher progression‐free survival (PFS) and a decrease in tumor burden compared to patients with TP53 wild‐type (p53 wt ) tumors but no difference in overall survival compared to patients with p53 wt tumors. The gene set enrichment analysis showed a uniform upregulation of multiple metabolic and immune gene sets, including NK‐mediated immunity and IL‐12 pathway, while the IL6 pathway was downregulated. There were no overlapping transcriptional alterations between the p53 mt and p53 wt groups with treatment that remain constant despite the therapeutic intervention. Functional overlap with treatment in both groups in the proliferative, immune, and metabolic pathways were identified. In the baseline tumor samples, the number of PD‐L1 + tumor cells was significantly higher in p53 mt tumors while the number of OX40 − /AE1_AE3 − /PD‐L1 − non‐tumor cells, positive for either LAG3, CTLA4 or TIM3, was significantly higher in p53 wt tumors. In conclusion, TP53 status was prognostic of improved PFS with cetuximab plus pembrolizumab in RAS wt CRC. Future studies evaluating immune‐oncology agents in patients with MSS, RAS wt CRC should include TP53 as an integrated biomarker and evaluate its performance as a positive predictive biomarker (ClinicalTrials.gov NCT02713373).
- Open Access
A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers
SUMMARY: The tumor suppressor TP53 gene (p53) is mutated in most human malignancies; however, existing treatment options are largely ineffective, lack selectivity, and cause toxic side effects. To address these clinical problems, we developed a sequential triple-drug strategy for p53 mutant cancer cells. Here we show that a combination of a thymidine analogue (TAS102) plus PARP inhibitor (PARPi) promotes formation of DNA double-strand breaks (DSBs) and G2-arrest specifically in p53 mutant cancer cells. Transcriptome analysis revealed that TAS102-PARPi treatment of p53 mutant cells did not repress DNA replication but activated DSB repair and blocked the mitotic program, consistent with G2-arrest. In contrast, TAS102-PARPi treatment of normal p53 wild-type cells resulted in a temporal G1-arrest and rapid recovery of cell cycle capacity after drug withdrawal. In p53 mutant cancer cells, subsequent blocking of a G2-checkpoint kinase, such as WEE1, released these G2-arrested cells into mitosis, leading to massive cell death. Delayed administration of a G2-kinase inhibitor provides time for p53 wild-type cells to repair DNA, thereby minimizing toxicity to normal tissues. This sequential triple-drug strategy exhibited robust efficacy in preclinical models of colorectal and pancreatic cancers and was well tolerated in mice. Together, our findings illustrate a promising triple-drug strategy for targeting p53 mutant malignancies.
Open AccessA Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers
SUMMARY: The tumor suppressor TP53 gene (p53) is mutated in most human malignancies; however, existing treatment options are largely ineffective, lack selectivity, and cause toxic side effects. To address these clinical problems, we developed a sequential triple-drug strategy for p53 mutant cancer cells. Here we show that a combination of a thymidine analogue (TAS102) plus PARP inhibitor (PARPi) promotes formation of DNA double-strand breaks (DSBs) and G2-arrest specifically in p53 mutant cancer cells. Transcriptome analysis revealed that TAS102-PARPi treatment of p53 mutant cells did not repress DNA replication but activated DSB repair and blocked the mitotic program, consistent with G2-arrest. In contrast, TAS102-PARPi treatment of normal p53 wild-type cells resulted in a temporal G1-arrest and rapid recovery of cell cycle capacity after drug withdrawal. In p53 mutant cancer cells, subsequent blocking of a G2-checkpoint kinase, such as WEE1, released these G2-arrested cells into mitosis, leading to massive cell death. Delayed administration of a G2-kinase inhibitor provides time for p53 wild-type cells to repair DNA, thereby minimizing toxicity to normal tissues. This sequential triple-drug strategy exhibited robust efficacy in preclinical models of colorectal and pancreatic cancers and was well tolerated in mice. Together, our findings illustrate a promising triple-drug strategy for targeting p53 mutant malignancies.
- Open Access
A Proteome-Wide Gain-of-Function Atlas Mapping the Landscape of Chemotherapy Response
Background: Conventional chemotherapies remain the core therapeutic backbone of cancer treatment, yet the rapid emergence of chemoresistance often compromises their clinical efficacy. Although large-scale functional genomics has transformed precision oncology, existing reference maps rely predominantly on loss-of-function paradigms and lack systematic data on gain-of-function (GOF) events that commonly drive clinical resistance. Methods: To address this gap, we engineered a site-specific Bxb1 integrase landing-pad system in HeLa cells, enabling single-copy integration of a human proteome-wide library [18,388 open reading frames (ORFs)] at the AAVS1 locus under a uniform EF1α promoter. We systematically profiled cellular fitness across 16 chemotherapeutics. We integrated this GOF perturbation screen with bulk and single-cell RNA sequencing, FACS-based lysosomal functional screening, clinical cohort survival analyses, and preclinical xenograft modeling. Results: Stratified modeling of over 230,000 gene-drug interactions defined distinct functional categories that are strongly enriched for clinical cancer biomarkers and prognostic relevance. Global network analysis and organelle-specific lysosomal functional screening uncovered that chemotherapeutic agents, most prominently the nucleoside analog TAS-102 (Lonsurf), converge upon a shared survival hub centered on the BCL-2 family-associated autophagy-endolysosomal network. Mechanistically, TAS-102 triggered lysosomal activation as an adaptive survival response. Co-treatment with the BCL-2 family inhibitor ABT-263 (Navitoclax) attenuated this TAS-102-induced lysosomal response and synergistically reversed TAS-102 resistance across colorectal and pancreatic cancer models in vitro and in colorectal cell line- and patient-derived xenograft (CDX, PDX) models in vivo . Conclusions: Our study establishes an open-access, proteome-wide GOF reference atlas that systematically maps chemotherapeutic responses, recapitulates canonical resistance biology, and nominates rational drug combinations. This systems-genomics resource bridges massive-scale perturbation mapping with actionable target discovery, providing a translational framework to overcome therapeutic resistance and reprogram cancer drug responses.
Open AccessA Proteome-Wide Gain-of-Function Atlas Mapping the Landscape of Chemotherapy Response
Background: Conventional chemotherapies remain the core therapeutic backbone of cancer treatment, yet the rapid emergence of chemoresistance often compromises their clinical efficacy. Although large-scale functional genomics has transformed precision oncology, existing reference maps rely predominantly on loss-of-function paradigms and lack systematic data on gain-of-function (GOF) events that commonly drive clinical resistance. Methods: To address this gap, we engineered a site-specific Bxb1 integrase landing-pad system in HeLa cells, enabling single-copy integration of a human proteome-wide library [18,388 open reading frames (ORFs)] at the AAVS1 locus under a uniform EF1α promoter. We systematically profiled cellular fitness across 16 chemotherapeutics. We integrated this GOF perturbation screen with bulk and single-cell RNA sequencing, FACS-based lysosomal functional screening, clinical cohort survival analyses, and preclinical xenograft modeling. Results: Stratified modeling of over 230,000 gene-drug interactions defined distinct functional categories that are strongly enriched for clinical cancer biomarkers and prognostic relevance. Global network analysis and organelle-specific lysosomal functional screening uncovered that chemotherapeutic agents, most prominently the nucleoside analog TAS-102 (Lonsurf), converge upon a shared survival hub centered on the BCL-2 family-associated autophagy-endolysosomal network. Mechanistically, TAS-102 triggered lysosomal activation as an adaptive survival response. Co-treatment with the BCL-2 family inhibitor ABT-263 (Navitoclax) attenuated this TAS-102-induced lysosomal response and synergistically reversed TAS-102 resistance across colorectal and pancreatic cancer models in vitro and in colorectal cell line- and patient-derived xenograft (CDX, PDX) models in vivo . Conclusions: Our study establishes an open-access, proteome-wide GOF reference atlas that systematically maps chemotherapeutic responses, recapitulates canonical resistance biology, and nominates rational drug combinations. This systems-genomics resource bridges massive-scale perturbation mapping with actionable target discovery, providing a translational framework to overcome therapeutic resistance and reprogram cancer drug responses.
- Open Access
p38 blockade reverses the immune suppressive tumor microenvironment in metastatic breast cancer
Metastatic breast cancer (MBC) is a life-threatening disease with limited therapeutic options. The immune suppressive tumor microenvironment (TME) limits the potency of the antitumor immune response and facilitates disease progression and metastasis. Our current study demonstrates that p38α is a druggable target in the TME that regulates the outcome of the immune-tumor interaction. The study revealed that systemic blockade of p38α reduces metastasis, and this anti-metastatic response is negated by depletion of CD8 + T cells. Single-cell transcriptomic analysis of the immune-TME showed that pharmacological p38 inhibition (p38i) or tumor-specific inactivation of p38α by CRISPR/Cas9 (p38KO) resulted in a less exhausted and more activated CD8 + T cell phenotype. Immunophenotyping analyses demonstrated that p38 blockade reduced the expression of multiple inhibitory receptors on CD8 + T cells (i.e., PD-1, LAG-3, CTLA-4), indicating a reversal of immune exhaustion and enhanced immune activation systemically and in the TME. In contrast, p38 blockade did not exhibit inhibitory effects on T cells in proliferation assays in vitro and did not affect the proportion of regulatory T cells in vivo . The major negative impact of p38 blockade in vivo was on the myeloid populations, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). Further, tumor p38α activity was required for the expression of cytokines/chemokines and tumor-derived exosomes with high chemotactic capacity for myeloid cells. Altogether, this study highlights a previously unrecognized p38α-driven pathway that promotes an immune suppressive TME and metastasis, and that therapeutic blockade of p38α has important implications for improving antitumor immunity and patient outcomes. STATEMENT OF SIGNIFICANCE: This study highlights a previously unrecognized p38α-driven tumor pathway that promotes an immune suppressive microenvironment and metastasis, and that therapeutic blockade of p38α has important implications for improving antitumor immunity and patient outcomes.
Open Accessp38 blockade reverses the immune suppressive tumor microenvironment in metastatic breast cancer
Metastatic breast cancer (MBC) is a life-threatening disease with limited therapeutic options. The immune suppressive tumor microenvironment (TME) limits the potency of the antitumor immune response and facilitates disease progression and metastasis. Our current study demonstrates that p38α is a druggable target in the TME that regulates the outcome of the immune-tumor interaction. The study revealed that systemic blockade of p38α reduces metastasis, and this anti-metastatic response is negated by depletion of CD8 + T cells. Single-cell transcriptomic analysis of the immune-TME showed that pharmacological p38 inhibition (p38i) or tumor-specific inactivation of p38α by CRISPR/Cas9 (p38KO) resulted in a less exhausted and more activated CD8 + T cell phenotype. Immunophenotyping analyses demonstrated that p38 blockade reduced the expression of multiple inhibitory receptors on CD8 + T cells (i.e., PD-1, LAG-3, CTLA-4), indicating a reversal of immune exhaustion and enhanced immune activation systemically and in the TME. In contrast, p38 blockade did not exhibit inhibitory effects on T cells in proliferation assays in vitro and did not affect the proportion of regulatory T cells in vivo . The major negative impact of p38 blockade in vivo was on the myeloid populations, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). Further, tumor p38α activity was required for the expression of cytokines/chemokines and tumor-derived exosomes with high chemotactic capacity for myeloid cells. Altogether, this study highlights a previously unrecognized p38α-driven pathway that promotes an immune suppressive TME and metastasis, and that therapeutic blockade of p38α has important implications for improving antitumor immunity and patient outcomes. STATEMENT OF SIGNIFICANCE: This study highlights a previously unrecognized p38α-driven tumor pathway that promotes an immune suppressive microenvironment and metastasis, and that therapeutic blockade of p38α has important implications for improving antitumor immunity and patient outcomes.
- Open Access
- 21 February 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (3) , 101434
A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers
- 21 February 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (3) , 101434
Open AccessA synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers